Thermo Fisher Scientific has scrapped its previously planned $11.5 billion acquisition of Qiagen after its offer to buy all of the ordinary shares of the latter lapsed. The US life sciences company announced the acquisition of the Netherlands-based provider of molecular diagnostics and sample preparation technologies in March 2020 in a move to expand specialty […]
Thermo Fisher acquisition of Qiagen : US life sciences company Thermo Fisher Scientific has agreed to acquire Qiagen, a Netherlands-based provider of molecular diagnostics and sample preparation technologies in an all-cash deal worth around $11.5 billion. The deal includes the assumption of nearly Qiagen’s $1.4 billion of net debt by the US firm. Thermo Fisher […]
Qiagen and DiaSorin have secured approval from the US Food and Drug Administration (FDA) to use QuantiFERON-TB Plus (QFT-Plus automated screening solution) on the latter’s LIAISON platforms for detecting latent tuberculosis (TB). With the FDA approval, Qiagen and Diasorin can perform laboratory automation for latent TB screening, which will support the conversion from tuberculin skin […]